Q4 acquires Euroinvestor IR Solutions
Q4 acquires Euroinvestor IR Solutions The preclinical data presented here suggest that these patients may benefit from PD-1 axis blockade if combined with poxvirus-based active immunotherapies that provoke a productive tumor-infiltrating CD8 T cell response. These data further suggest that the evolution of tumors from PD-L1neg/low kryptovaluta to PD-L1hi may be useful as a biomarker for the emergence of productive anti-tumor T cell immunity. Antigen spread is thought to play a critical role in successful immunotherapy as the immune system adapts to target novel tumor antigens as well as restricts tumor evasion to therapy. Tumor Cell Lines Conversely, without an endogenous anti-cancer T cell immune response, as presumed in cancer patients harboring PD-L1neg/low tumors, the immune checkpoint blockade is unfocused and not expected to confer significant clinical benefit . We hypothesized that poxvirus-based immunotherapy would drive antigen-specific T cells to the tumor, concomitant w...